AVIR
Atea Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.39
+1.62%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -23.0%
- EBIT
- -17.2%
- EPS
- -29.2%
- Free cash flow
- -30.1%
- Operating cash flow
- -30.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +73.4%
- EPS
- +8.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- -24.5%
- EBIT
- +6.3%
- Net income
- +6.0%
- EPS
- +3.0%
- Free cash flow
- +2.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026